Terrie Curran Sells 8,687 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Director Terrie Curran sold 8,687 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $10.85, for a total transaction of $94,253.95. Following the completion of the transaction, the director now directly owns 10,139 shares of the company’s stock, valued at approximately $110,008.15. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Arcutis Biotherapeutics Stock Performance

Arcutis Biotherapeutics stock opened at $10.47 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.46 and a quick ratio of 2.38. The firm has a market capitalization of $1.23 billion, a P/E ratio of -5.85 and a beta of 1.18. Arcutis Biotherapeutics, Inc. has a 1-year low of $1.76 and a 1-year high of $13.17. The company’s 50-day moving average is $9.66 and its 200 day moving average is $9.35.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.09. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%. The firm had revenue of $44.76 million for the quarter, compared to the consensus estimate of $38.05 million. Research analysts forecast that Arcutis Biotherapeutics, Inc. will post -1.34 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ARQT. Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Arcutis Biotherapeutics in a research note on Thursday, November 7th. Jefferies Financial Group started coverage on Arcutis Biotherapeutics in a research report on Wednesday, August 28th. They issued a “buy” rating and a $15.00 price target for the company.

Institutional Trading of Arcutis Biotherapeutics

A number of large investors have recently made changes to their positions in the stock. CWM LLC increased its stake in Arcutis Biotherapeutics by 6,740.0% in the 2nd quarter. CWM LLC now owns 4,104 shares of the company’s stock worth $38,000 after buying an additional 4,044 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Arcutis Biotherapeutics by 55.2% during the first quarter. Ameritas Investment Partners Inc. now owns 7,871 shares of the company’s stock worth $78,000 after acquiring an additional 2,800 shares during the period. Algert Global LLC bought a new stake in shares of Arcutis Biotherapeutics during the second quarter valued at approximately $97,000. Victory Capital Management Inc. boosted its holdings in shares of Arcutis Biotherapeutics by 9.9% in the third quarter. Victory Capital Management Inc. now owns 12,843 shares of the company’s stock valued at $119,000 after purchasing an additional 1,155 shares during the period. Finally, Creative Planning bought a new position in Arcutis Biotherapeutics in the third quarter worth approximately $127,000.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.